StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued on Tuesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of NASDAQ EGRX opened at $1.23 on Tuesday. The company’s 50-day moving average price is $0.80 and its 200 day moving average price is $1.70. Eagle Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $6.81.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of EGRX. DGS Capital Management LLC lifted its stake in Eagle Pharmaceuticals by 44.9% in the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after buying an additional 22,239 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Eagle Pharmaceuticals in the third quarter worth $96,000. RBF Capital LLC lifted its position in shares of Eagle Pharmaceuticals by 11.7% in the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after acquiring an additional 14,991 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Eagle Pharmaceuticals during the third quarter valued at $453,000. Finally, Creative Planning purchased a new stake in Eagle Pharmaceuticals during the 3rd quarter worth about $59,000. 85.36% of the stock is owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.